RESEARCH MONOGRAPH · KDC-MN-228

Moclobemide

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

76/100

The reversible MAO-A inhibitor that should have replaced the irreversibles and almost did

Moclobemide is the RIMA that more or less solved the tyramine problem that plagued classical MAOIs. The mechanism is reversible competitive MAO-A inhibition, which means when dietary tyramine hits the gut and pushes through into circulation, it can outcompete moclobemide at the MAO-A active site and get metabolized normally. So the pressor crisis risk that made phenelzine and tranylcypromine dietary nightmares is essentially gone with moclobemide at standard exposures.

What we like is the cleanness of the pharmacology. Selective MAO-A inhibition, reversible, well-behaved kinetics, no covalent warhead. If you're studying MAO-A contribution to monoamine catabolism specifically, moclobemide is a much better probe than non-selective irreversibles because you can wash it out and you don't have to wait two weeks for new enzyme synthesis.

The clinical story is more interesting than the modern Western literature suggests. Moclobemide has been widely used in Europe, Latin America, and parts of Asia for depression and social anxiety disorder, with effect sizes that hold up reasonably well against SSRIs. It never got FDA approval in the US, which is mostly a story about timing and commercial decisions rather than efficacy. Honestly we think that's been a loss for the American antidepressant pipeline because the RIMA mechanism remains underexplored.

For research the half-life is short, which is actually useful for animal pharmacology because it lets you do clean on-off paradigms without having to wait through long irreversible kinetics. CYP2C19 handles most of the metabolism, with some 2D6 contribution.

What we dont like is mostly the marketing-and-availability picture. Moclobemide is a perfectly sensible clinical compound that just never reached the audience it deserved, and the modern psychopharm community in the US largely doesn't think about it because nobody had a commercial interest in promoting it.

Sourcing is fine where its sold, with reasonable reference material available. HPLC validation is standard. Per-gram costs are moderate.

Slept-on tool compound for selective MAO-A work, and underrated in the broader MAOI conversation.

Evidence: 80
Mechanism: 88
Reliability: 78
Safety: 82
Sourcing: 75
Value: 72
Signal: 65
Staying power: 65

Plain-language summary Intrigue 62 / 100

Moclobemide (Aurorix) was a major step forward in MAOI design: it blocks MAO-A reversibly rather than permanently, which means dietary tyramine can simply outcompete the drug at the enzyme rather than triggering a crisis. That eliminates the dreaded cheese-effect that has held the older MAOIs back for sixty years. Roche brought it to market in Europe in 1989 and in Canada in 1992, but it never received FDA approval in the US, partly because the company's Phase 3 trials were not designed to American regulatory standards. Efficacy in depression and social anxiety is solid in European data, comparable to SSRIs. Without the FDA stamp it remains underused in North American practice, which is unfortunate because it is genuinely a more elegant drug than its first-generation predecessors. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Reversible MAO-A inhibitor (RIMA)

A morpholine benzamide reversible inhibitor of MAO-A (RIMA); the first MAOI that does not require dietary tyramine restriction.

Abstract

Moclobemide (4-chloro-N-(2-morpholin-4-ylethyl)benzamide; CAS 71320-77-9; molecular formula C13H17ClN2O2; molecular weight 268.74) is a morpholine benzamide reversible inhibitor of MAO-A (RIMA) developed at Roche and approved in Europe (1989) and Canada (1992) under the trade name Aurorix; never FDA approved for the US market. Distinct from earlier MAOIs by reversible binding: tyramine and other dietary substrates can displace moclobemide from MAO-A, eliminating the requirement for tyramine restriction at typical clinical doses. MAO-A selectivity ratio is approximately 100:1 over MAO-B at low doses. Plasma half-life is 1 to 4 hours; the short half-life dictates twice-daily dosing. Hepatic metabolism via CYP2C19 is the primary clearance pathway. Approved for major depressive disorder and social anxiety disorder. The eliminated tyramine restriction has not produced the expected clinical takeoff: efficacy is modestly inferior to TCAs in head-to-head trials, and the drug remains a niche option. Used as the canonical RIMA in mechanism studies.

Mechanism of action

Reversible selective MAO-A inhibition. Tyramine displaces moclobemide from the enzyme, eliminating cheese-effect risk at clinical doses.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev 2003.
Lotufo-Neto F, et al. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 1999.
Fulton B, Benfield P. Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs 1996.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-228

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Moclobemide

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs